US biotech agency Novavax stated Monday it had began medical trials of its proposed Covid-19 vaccine on kids, in a program that may contain as much as 3,000 adolescents aged 12-17.
Far fewer kids have been sick with Covid-19 in comparison with adults, and most have delicate to no signs, however they are often contaminated and unfold the virus.
Novavax stated the trials would check “the efficacy (and) security” of the vaccine, with individuals receiving both the vaccine candidate or placebo in two doses, 21 days aside.
Contributors can be monitored for as much as two years after their injections.
The Novavax vaccine has not but been approved in any nation, together with for adults, however the firm plans to file for emergency authorization in Britain “within the second quarter of 2021”, adopted by in the USA.
Novavax introduced on the finish of January that medical trials performed in Britain involving 15,000 adults confirmed 89.Three % efficacy.
The Novavax vaccine, which makes use of completely different know-how from the doses already extensively licensed around the globe, is a protein-based vaccine engineered from the genetic sequence of the primary pressure of the coronavirus.
It may be saved at a temperature between 2 and eight levels Celsius (35 – 46.four levels Fahrenheit).
Different vaccine corporations together with Moderna, Johnson & Johnson and Pfizer are additionally conducting trials in adolescents.
Europe’s medicines watchdog stated Monday it had begun evaluating the usage of Pfizer/BioNTech’s vaccine for 12- to 15-year-olds, after the same request in the USA.
Vaccine authorization for youngsters is seen as a vital step in direction of reaching herd immunity.
(Apart from the headline, this story has not been edited by NDTV workers and is printed from a syndicated feed.)